Nykode Therapeutics to present interim head and neck cancer data

Nykode Therapeutics ASA is set to present interim data from its VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) in Seville, Spain, on March 20, 2026, between 15:15-16:15 CET. The trial is evaluating abi-suva in combination with KEYTRUDA® (pembrolizumab) for first-line unresectable recurrent or metastatic head and neck cancer patients. The abstract for the presentation is expected to be published on February 19, 2026. This presentation aligns with Nykode's strategy to further investigate abi-suva in this patient population.

The company's chief executive, Michael Engsig, highlighted the importance of providing further insight into the C-03 clinical data. Nykode is also advancing abi-suva development in first-line head and neck cancer through the Abili-T phase 2 randomized controlled trial. Engsig, along with chief scientific officer and co-founder Agnete Fredriksen, will also be attending the 44th Annual J.P. Morgan Healthcare Conference, available for one-on-one meetings.

Nykode Therapeutics, a clinical-stage biopharmaceutical company, focuses on immunotherapies for cancer and autoimmune diseases. Their modular technology targets antigens to antigen-presenting cells, aiming to induce robust, long-lasting immune responses. Beyond abi-suva, which previously showed favorable safety and efficacy in HPV16-induced cervical cancer, Nykode is also developing VB10.NEO for individualized cancer neoantigen immunotherapy and an immune tolerance platform for autoimmune disorders.